Fat Malabsorption in Chronic Pancreatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 13, 2016

Primary Completion Date

November 1, 2017

Study Completion Date

November 1, 2017

Conditions
Chronic Pancreatitis
Interventions
DRUG

Creon36™

Creon36™ delayed-release capsules, a pancreatic enzyme preparation, is an FDA approved medication. Subjects with chronic pancreatitis (CP) will take Creon36™ for nine days, at a daily dose of 72,000 lipase units per meal (two capsules) and 36,000 units per snack (one capsule), with each capsule containing 36,000 lipase units. Subjects will take Creon36™ for three days prior to Visit 2, the day of Visit 2 and then for five days after the visit until they have completed stool collections.

Trial Locations (1)

19104

Children's Hospital of Philadelphia, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Phoenix Indian Medical Center

UNKNOWN

lead

Children's Hospital of Philadelphia

OTHER